Additional approval bolsters Amgen cancer treatment
Correction: The headline on this article has been updated. The U.S. Food and Drug Administration has approved Amgen’s supplemental biologics license for Blincyto, which treats adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia, the Thousand Oaks-based life sciences giant announced on June 20. The patients have the leukemia in first or second Read More →
New public biotech firm joins Conejo Valley cluster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s $28B merger bid gets tougher
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Fresh coat of paint: Amgen’s new mural pays homage to diversity in biotech
Update: A previous version of this article mistakenly quoted Janet Franklin instead of Sarah Van Driesche. When Amgen scientist Sarah Van Driesche attended an awards program at Rockefeller University in New York prior to the pandemic, she took note of a mural depicting top scientists from the institute. A casual remark about “what’s with up the Read More →
Innovative medical procedure makes its way to Ventura County
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.